|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
Rempex Raises $67.5M, Vertex Shares Tumble, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
11/10/11 |
San Diego
|
|
Vertex Sales Much Bigger Than Expected, Amylin Re-Submits Exenatide, Mini VC Fund Debuts, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
08/04/11 |
San Diego
|
|
Trius and Bayer Sign Deal, Brooks Buys Nexus Biosystems, Wildcat Discovery Gets $7.5M Financing, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
07/28/11 |
San Diego
|
|
A San Diego Sampler from the War on Diabetes
|
Bruce V. Bigelow |
06/24/11 |
San Diego
|
|
Inception 1 Raises $5M, VCs Pessimistic About U.S. Biotech Funding, EU Approves Amylin’s Once-a-Week Diabetes Drug, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/23/11 |
San Diego
|
|
Orexigen Halts U.S. Work on Weight Loss Drug, Illumina Cuts Price for Sequencing Patient Genomes, Ambit Pulls IPO, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/09/11 |
San Diego
|
|
Amylin Gets TRO Against Lilly
|
Bruce V. Bigelow |
05/26/11 |
San Diego
|
|
Shire Pays $750M for Advanced BioHealing, Amylin Sues Lilly, Pacira CEO Describes His Most Difficult Task, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
05/19/11 |
San Diego
|
|
Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug
|
Luke Timmerman |
05/16/11 |
San Diego
|
|
Lilly Funds Cerulean, Genzyme Sells Diagnostics Unit, Roche Ends RNAi Program, & More Boston-Area Life Sciences News
|
Erin Kutz |
11/19/10 |
Boston
|
|
Alkermes Drops on FDA Rejection, Glaxo’s SR One Backs Dicerna, Biogen Reworks Genentech Alliance, & More Boston-Are Life Sciences News
|
Erin Kutz |
10/22/10 |
Boston
|
|
Sequenom Restarts Down Syndrome Test, Cytori Upbeat About Cardiac Study, Pathway Genomics Mass Markets Genome Tests, & More San Diego Life Sciences News
|
Denise Gellene |
05/13/10 |
San Diego
|
|
Novartis Buys Alnylam Shares, Xconomy Holds First Ever Health IT Forum, Vertex Alumni Spread Throughout Life Sciences Sector, & More Boston-Area Life Sciences News
|
Erin Kutz |
04/30/10 |
Boston
|
|
Warner Bros. Acquires Turbine, Athenahealth Taps IBM, Alkermes Reveals Diabetes Drug Royalty, & More Boston-Area Deals News
|
Erin Kutz |
04/28/10 |
Boston
|
|
Amylin CEO, Putting Boardroom Coup Behind Him, Turns Up Heat on New Diabetes Drug
|
Luke Timmerman |
09/29/09 |
San Diego
|
|
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/11/09 |
San Diego
|
|
Amylin Founder Ted Greene, In Exclusive Interview, Upbeat About Outcome of Proxy Battle
|
Bruce V. Bigelow |
06/02/09 |
San Diego
|
|
Vical Developing Vaccine for Swine Flu, Acadia’s Stock Almost Doubles on Biovail Deal, Qualcomm Launches Business Plan Contest, & Other San Diego BizTech News
|
Bruce V. Bigelow |
05/11/09 |
San Diego
|
|
Diabetes Drug Application May Be New Factor in Amylin Proxy Battle
|
Juha-Pekka Tikka |
05/05/09 |
San Diego
|
|
Amylin Braces for Proxy Battle Amid Flurry of Filings
|
Bruce V. Bigelow |
04/09/09 |
San Diego
|
|
Amylin Shares Soar as Diabetes Drug Catches a Break From FDA
|
Luke Timmerman |
12/11/08 |
San Diego
|
|
Biotech Survival Index: Cash Woes Creeping Up on San Diego Life Sciences Companies
|
Luke Timmerman |
11/18/08 |
San Diego
|
|
Aileron Develops New Class of Drugs To Go Where None Could Before
|
Luke Timmerman |
11/07/08 |
Boston
|
|
Amylin, Alkermes Shares Plunge On Possible FDA Delays
|
Luke Timmerman |
11/04/08 |
San Diego
|
|
Amylin Shareholder Floats Idea of Selling Company
|
Luke Timmerman |
11/04/08 |
San Diego
|
|
Amylin Gets $125M from Eli Lilly To Make Once-Weekly Diabetes Drug
|
Luke Timmerman |
10/21/08 |
San Diego
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.